Treatment of Psoriasis: A Comprehensive Review of Entire Therapies

Author(s): Harman Bakshi, Manju Nagpal*, Manjinder Singh, Gitika Arora Dhingra, Geeta Aggarwal

Journal Name: Current Drug Safety

Volume 15 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Psoriasis is an autoimmune disease that ingeminates itself with the repeated proliferation of keratinocytes. It globally strikes a 2-5 % population on an average. Management of psoriasis remains a daunting task with various challenges influencing treatment, such as patient conformity and adherence to therapy, delicate patient profiles, psychological aspects, and skin as a barrier to topical delivery. The first part reviewed pathophysiology, triggering factors, and clinical classification. The second part reviewed all the therapies, such as topical, oral, biological, parenteral therapy, phototherapy, and the phyto-pharmaceuticals.

Methods: The research data related to the existing and upcoming therapies for psoriasis treatment, several nanocarriers, existing marketed formulations, and detailed description of phytopharmaceuticals with their mechanism.

Results: Topical therapy is the mainstay treatment option with limited adverse effects. Biological therapy has reformed conventional psoriasis treatment by being more efficacious and has increased patient acceptance due to decreased adverse events. Nanoformulations present an edge over conventional therapy due to improved anti-psoriatic effect and decreased side effects. Phyto-pharmaceuticals act as a complementary and alternative therapy for diminishing psoriasis symptoms.

Conclusion: A rationalized cost-effective patient compliant therapy is required for effective management and complete cure of psoriasis.

Keywords: Topical, nanoformulations, autoimmune, challenges, psychological, symptomatic.

[1]
Sala M, Elaissari A, Fessi H. Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Control Release 2016; 239: 182-202.
[http://dx.doi.org/10.1016/j.jconrel.2016.07.003] [PMID: 27381248]
[2]
Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014; 32: 227-55.
[http://dx.doi.org/10.1146/annurev-immunol-032713-120225] [PMID: 24655295]
[3]
Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol 2013; 168(6): 1303-10.
[http://dx.doi.org/10.1111/bjd.12230] [PMID: 23374051]
[4]
Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49(2): S44-50.
[http://dx.doi.org/10.1016/S0190-9622(03)01134-4] [PMID: 12894125]
[5]
Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9(6): 461-7.
[http://dx.doi.org/10.1007/s11926-007-0075-1] [PMID: 18177599]
[6]
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017; 140(3): 645-53.
[http://dx.doi.org/10.1016/j.jaci.2017.07.004] [PMID: 28887948]
[7]
Eberle FC, Brück J, Holstein J, Hirahara K, Ghoreschi K. Recent advances in understanding psoriasis. F1000 Res 2016; 5: 5.
[http://dx.doi.org/10.12688/f1000research.7927.1] [PMID: 27158469]
[8]
Pradhan M, Singh D, Singh MR. Influence of selected variables on fabrication of Triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders. Artif Cells Nanomed Biotechnol 2016; 44(1): 392-400.
[http://dx.doi.org/10.3109/21691401.2014.955105] [PMID: 25229831]
[9]
Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol 2015; 135(12): 2955-63.
[http://dx.doi.org/10.1038/jid.2015.296] [PMID: 26214380]
[10]
Gupta R, Debbaneh MG, Liao W. Genetic epidemiology of psoriasis. Curr Dermatol Rep 2014; 3(1): 61-78.
[http://dx.doi.org/10.1007/s13671-013-0066-6] [PMID: 25580373]
[11]
Griffiths CEM, van der Walt JM, et al. The global state of psoriasis disease epidemiology: A workshop report. Br J Dermatol 2017; 177(1): e4-7.
[http://dx.doi.org/10.1111/bjd.15610] [PMID: 28555722]
[12]
Gudjonsson JE, Elder JT. Psoriasis: Epidemiology. Clin Dermatol 2007; 25(6): 535-46.
[http://dx.doi.org/10.1016/j.clindermatol.2007.08.007] [PMID: 18021890]
[13]
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: A population-based study. J Am Acad Dermatol 2009; 60(3): 394-401.
[http://dx.doi.org/10.1016/j.jaad.2008.10.062] [PMID: 19231638]
[14]
Bhatia A, Singh B, Wadhwa S, Raza K, Katare OP. Novel phospholipid-based topical formulations of tamoxifen: Evaluation for antipsoriatic activity using mouse-tail model. Pharm Dev Technol 2014; 19(2): 160-3.
[http://dx.doi.org/10.3109/10837450.2013.763260] [PMID: 23369039]
[15]
Schadler ED, Ortel B, Mehlis SL. Biologics for the primary care physician: Review and treatment of psoriasis. Dis Mon 2019; 65(3): 51-90.
[http://dx.doi.org/10.1016/j.disamonth.2018.06.001] [PMID: 30037762]
[16]
Tagami H. Triggering factors. Clin Dermatol 1997; 15(5): 677-85.
[http://dx.doi.org/10.1016/S0738-081X(97)00024-2] [PMID: 9313966]
[17]
Baker BS, Swain AF, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984; 110(5): 555-64.
[http://dx.doi.org/10.1111/j.1365-2133.1984.tb04678.x] [PMID: 6232938]
[18]
Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009; 55(1): 62-3.
[http://dx.doi.org/10.1016/j.jdermsci.2009.02.009] [PMID: 19395243]
[19]
Kumar S, Han J, Li T, Qureshi AA, Choi HK, Qureshi AA. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 2013; 27(10): 1293-8.
[PMID: 23057623]
[20]
Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15(5 Pt 1): 1007-22.
[http://dx.doi.org/10.1016/S0190-9622(86)70265-X] [PMID: 2878015]
[21]
Sondergaard J, Wadskov S, Jensen HA, Mikkelsen HI. Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin). Acta Derm Venereol 1976; 56(3): 239-43.
[PMID: 59510]
[22]
Seville RH. Psoriasis and stress. Br J Dermatol 1977; 97(3): 297-302.
[http://dx.doi.org/10.1111/j.1365-2133.1977.tb15186.x] [PMID: 921900]
[23]
Zhou C, Yu X, Cai D, Liu C, Li C. Role of corticotropin-releasing hormone and receptor in the pathogenesis of psoriasis. Med Hypotheses 2009; 73(4): 513-5.
[http://dx.doi.org/10.1016/j.mehy.2009.02.051] [PMID: 19560286]
[24]
Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: Evidence from an Italian case-control study. Arch Dermatol 1999; 135(12): 1479-84.
[http://dx.doi.org/10.1001/archderm.135.12.1479] [PMID: 10606053]
[25]
Mills CM, Srivastava ED, Harvey IM, et al. Smoking habits in psoriasis: A case control study. Br J Dermatol 1992; 127(1): 18-21.
[http://dx.doi.org/10.1111/j.1365-2133.1992.tb14818.x] [PMID: 1637689]
[26]
Henseler T. The genetics of psoriasis. J Am Acad Dermatol 1997; 37(2 Pt 3): S1-S11.
[http://dx.doi.org/10.1016/S0190-9622(97)80394-5] [PMID: 9270550]
[27]
Dunna SF, Finlay AY. Psoriasis: Improvement during and worsening after pregnancy. Br J Dermatol 1989; 120(4): 584-4.
[http://dx.doi.org/10.1111/j.1365-2133.1989.tb01338.x] [PMID: 2730848]
[28]
Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445(7130): 866-73.
[http://dx.doi.org/10.1038/nature05663] [PMID: 17314973]
[29]
Schons KRR, Knob CF, Murussi N, Beber AAC, Neumaier W, Monticielo OA. Nail psoriasis: A review of the literature. An Bras Dermatol 2014; 89(2): 312-7.
[http://dx.doi.org/10.1590/abd1806-4841.20142633] [PMID: 24770509]
[30]
Piraccini BM, Starace M. Nail psoriasis in special populations: Children, pregnant, elderly. In: Rigopoulos D, Tosti A, Eds.Nail Psoriasis. Switzerland: Springer 2014; pp. 131-47.
[31]
Baran R, Tosti A. Nails. In: Fitzpatrick TB, Freedberg IM, Eds. Fitzpatrick’s dermatology in general medicine. 6th ed. New York: McGraw-Hill. Medical Pub Division 2003.
[32]
de Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg 2009; 28(1): 39-43.
[http://dx.doi.org/10.1016/j.sder.2008.12.003] [PMID: 19341941]
[33]
Yen YF, Jen IA, Chen M, et al. HIV infection increases the risk of incident psoriasis: A nationwide population-based cohort study in Taiwan. J Acquir Immune Defic Syndr 2017; 75(5): 493-9.
[http://dx.doi.org/10.1097/QAI.0000000000001431] [PMID: 28692580]
[34]
Fife DJ, Waller JM, Jeffes EW, Koo JY. Unraveling the paradoxes of HIV-associated psoriasis: A review of T-cell subsets and cytokine profiles. Dermatol Online J 2007; 13(2): 4.
[PMID: 17498423]
[35]
Itoi-Ochi S, Hayashi M, Yamaoka T, et al. Occult HIV infection in Japanese rupioid psoriasis. J Dermatol 2017; 44(7): e172-3.
[http://dx.doi.org/10.1111/1346-8138.13850] [PMID: 28452173]
[36]
Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997; 133(6): 711-5.
[http://dx.doi.org/10.1001/archderm.1997.03890420043005] [PMID: 9197824]
[37]
Allen BR. Use of cyclosporin for psoriasis in HIV-positive patient. Lancet 1992; 339(8794): 686.
[http://dx.doi.org/10.1016/0140-6736(92)90852-T] [PMID: 1347382]
[38]
Kim GW, Jung HJ, Ko HC, et al. Dermoscopy can be useful in differentiating scalp psoriasis from seborrhoeic dermatitis. Br J Dermatol 2011; 164(3): 652-6.
[http://dx.doi.org/10.1111/j.1365-2133.2010.10180.x] [PMID: 21155753]
[39]
El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: Not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol 2004; 26(5): 364-6.
[http://dx.doi.org/10.1097/00000372-200410000-00003] [PMID: 15365366]
[40]
Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R. Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways. Autoimmun Rev 2013; 12(5): 599-606.
[http://dx.doi.org/10.1016/j.autrev.2012.10.002] [PMID: 23183378]
[41]
Apel M, Uebe S, Bowes J, et al. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum 2013; 65(5): 1224-31.
[http://dx.doi.org/10.1002/art.37885] [PMID: 23401011]
[42]
Chen Z, O’Shea JJ. Th17 cells: A new fate for differentiating helper T cells. Immunol Res 2008; 41(2): 87-102.
[http://dx.doi.org/10.1007/s12026-007-8014-9] [PMID: 18172584]
[43]
Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65(12): 1608-12.
[http://dx.doi.org/10.1136/ard.2005.050377] [PMID: 16793844]
[44]
Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: Current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012; 71(3): 319-26.
[http://dx.doi.org/10.1136/ard.2011.150995] [PMID: 21803753]
[45]
Ko HC, Jwa SW, Song M, Kim MB, Kwon KSKO. Clinical course of guttate psoriasis: Long-term follow-up study. J Dermatol 2010; 37(10): 894-9.
[http://dx.doi.org/10.1111/j.1346-8138.2010.00871.x] [PMID: 20860740]
[46]
Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172(6): 298-304.
[http://dx.doi.org/10.1159/000249365] [PMID: 3089849]
[47]
Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007; 25(6): 529-34.
[http://dx.doi.org/10.1016/j.clindermatol.2007.08.006] [PMID: 18021889]
[48]
Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010; 23(2): 114-8.
[http://dx.doi.org/10.1111/j.1529-8019.2010.01304.x] [PMID: 20415817]
[49]
Tobin AM, Hughes R, Hand EB, Leong T, Graham IM, Kirby B. Homocysteine status and cardiovascular risk factors in patients with psoriasis: A case-control study. Clin Exp Dermatol 2011; 36(1): 19-23.
[http://dx.doi.org/10.1111/j.1365-2230.2010.03877.x] [PMID: 20545954]
[50]
Schmitt J, Ford DE. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling approach. Gen Hosp Psychiatry 2007; 29(2): 134-40.
[http://dx.doi.org/10.1016/j.genhosppsych.2006.12.004] [PMID: 17336662]
[51]
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83(12): 1583-90.
[http://dx.doi.org/10.1016/j.bcp.2012.01.001] [PMID: 22257911]
[52]
Lees CW, Satsangi J. Genetics of inflammatory bowel disease: Implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol 2009; 3(5): 513-34.
[http://dx.doi.org/10.1586/egh.09.45] [PMID: 19817673]
[53]
Morison WL, Baughman RD, Day RM, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134(5): 595-8.
[http://dx.doi.org/10.1001/archderm.134.5.595] [PMID: 9606329]
[54]
Yu Y, Sheth N, Krishnamoorthy P, et al. Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: A pilot study. Am J Cardiovasc Dis 2012; 2(4): 285-92.
[PMID: 23173102]
[55]
Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg 2004; 8(5): 310-20.
[http://dx.doi.org/10.1177/120347540400800502] [PMID: 15868312]
[56]
Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: Results from a European survey. J Eur Acad Dermatol Venereol 2005; 19(Suppl. 3): 2-6.
[http://dx.doi.org/10.1111/j.1468-3083.2005.01329.x] [PMID: 16274404]
[57]
Dogra S, Yadav S. Acitretin in psoriasis: An evolving scenario. Int J Dermatol 2014; 53(5): 525-38.
[http://dx.doi.org/10.1111/ijd.12365] [PMID: 24601982]
[58]
Montesinos MC, Desai A, Delano D, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003; 48(1): 240-7.
[http://dx.doi.org/10.1002/art.10712] [PMID: 12528125]
[59]
Elango T, Dayalan H, Gnanaraj P, Malligarjunan H, Subramanian S. Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. Clin Exp Med 2014; 14(4): 431-7.
[http://dx.doi.org/10.1007/s10238-013-0252-7] [PMID: 23949337]
[60]
Salvarani C, Boiardi L, Macchioni P, Pipitone N, Catanoso M, Pigatto P. Multidisciplinary focus on cyclosporin A. J Rheumatol Suppl 2009; 83: 52-5.
[http://dx.doi.org/10.3899/jrheum.090225] [PMID: 19661542]
[61]
Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73(1): 37-49.
[http://dx.doi.org/10.1016/j.jaad.2015.03.049] [PMID: 26089047]
[62]
Balak DM. Fumaric acid esters in the management of psoriasis. Psoriasis (Auckl) 2015; 5: 9-23.
[http://dx.doi.org/10.2147/PTT.S51490] [PMID: 29387578]
[63]
Pedraz J, Daudén E, Delgado-Jiménez Y, García-Río I, García-Díez A. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin. J Eur Acad Dermatol Venereol 2006; 20(6): 702-6.
[http://dx.doi.org/10.1111/j.1468-3083.2006.01577.x] [PMID: 16836499]
[64]
Wong T, Hsu L, Liao W. Phototherapy in psoriasis: A review of mechanisms of action. J Cutan Med Surg 2013; 17(1): 6-12.
[http://dx.doi.org/10.2310/7750.2012.11124] [PMID: 23364144]
[65]
Vide J, Magina S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. An Bras Dermatol 2017; 92(5): 668-74.
[http://dx.doi.org/10.1590/abd1806-4841.20175603] [PMID: 29166504]
[66]
Mervic L. Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics. Acta Dermatovenerol Alp Panonica Adriat 2014; 23(2): 27-31.
[http://dx.doi.org/10.15570/actaapa.2014.7] [PMID: 24964946]
[67]
Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144(12): 1571-5.
[http://dx.doi.org/10.1001/archderm.144.12.1571] [PMID: 19075139]
[68]
Badaoui A, Tounian P, Mahé E. Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review. Arch Pediatr 2019; 26(2): 86-94.
[http://dx.doi.org/10.1016/j.arcped.2018.12.005] [PMID: 30638928]
[69]
Thomas J, Parimalam K. Treating pediatric plaque psoriasis: Challenges and solutions. Pediatric Health Med Ther 2016; 7: 25-38.
[http://dx.doi.org/10.2147/PHMT.S75834] [PMID: 29388608]
[70]
Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174(1): 164-73.
[http://dx.doi.org/10.4049/jimmunol.174.1.164] [PMID: 15611238]
[71]
Roberson ED, Bowcock AM. Psoriasis genetics: Breaking the barrier. Trends Genet 2010; 26(9): 415-23.
[http://dx.doi.org/10.1016/j.tig.2010.06.006] [PMID: 20692714]
[72]
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: Findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013; 149(10): 1180-5.
[http://dx.doi.org/10.1001/jamadermatol.2013.5264] [PMID: 23945732]
[73]
Nast A, Boehncke WH, Mrowietz U, et al. Guidelines on the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2012; 10(Suppl. 2): S1-S95.
[http://dx.doi.org/10.1111/j.1610-0387.2012.07919.x] [PMID: 22386073]
[74]
Thorneloe RJ, Bundy C, Griffiths CEM, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: A systematic literature review. Br J Dermatol 2013; 168(1): 20-31.
[http://dx.doi.org/10.1111/bjd.12039] [PMID: 22963128]
[75]
Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: A systematic review. Der-matology (Basel) 2011; 222(4): 363-74.
[http://dx.doi.org/10.1159/000329026] [PMID: 21757881]
[76]
Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther (Heidelb) 2015; 28(6): 390-403.
[http://dx.doi.org/10.1111/dth.12267] [PMID: 26258910]
[77]
Griffiths CEM, Richards HL. Psychological influences in psoriasis. Clin Exp Dermatol 2001; 26(4): 338-42.
[http://dx.doi.org/10.1046/j.1365-2230.2001.00834.x] [PMID: 11422186]
[78]
Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS. Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national survey. J Am Acad Dermatol 2005; 52(3 Pt 1): 434-44.
[http://dx.doi.org/10.1016/j.jaad.2004.10.862] [PMID: 15761421]
[79]
Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140(4): 408-14.
[http://dx.doi.org/10.1001/archderm.140.4.408] [PMID: 15096368]
[80]
Bhandari KH, Lee DX, Newa M, et al. Evaluation of skin permeation and accumulation profiles of a highly lipophilic fatty ester. Arch Pharm Res 2008; 31(2): 242-9.
[http://dx.doi.org/10.1007/s12272-001-1148-8] [PMID: 18365697]
[81]
Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: A targeted approach for the treatment of psoriasis. Mol Pharm 2014; 11(9): 2989-3001.
[http://dx.doi.org/10.1021/mp400639e] [PMID: 25057896]
[82]
Dragicevic-Curic N, Winter S, Stupar M, et al. Temoporfin-loaded liposomal gels: Viscoelastic properties and in vitro skin penetration. Int J Pharm 2009; 373(1-2): 77-84.
[http://dx.doi.org/10.1016/j.ijpharm.2009.02.010] [PMID: 19429291]
[83]
Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm 2012; 427(2): 426-34.
[http://dx.doi.org/10.1016/j.ijpharm.2012.01.045] [PMID: 22310459]
[84]
Wadhwa S, Singh B, Sharma G, Raza K, Katare OP. Liposomal fusidic acid as a potential delivery system: A new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv 2016; 23(4): 1204-13.
[http://dx.doi.org/10.3109/10717544.2015.1110845] [PMID: 26592918]
[85]
Raza K, Singh B, Lohan S, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompat-ibility and anti-psoriatic activity. Int J Pharm 2013; 456(1): 65-72.
[http://dx.doi.org/10.1016/j.ijpharm.2013.08.019] [PMID: 23973754]
[86]
Jin Y, Zhang X, Zhang B, Kang H, Du L, Li M. Nanostructures of an amphiphilic zinc phthalocyanine polymer conjugate for photo-dynamic therapy of psoriasis. Colloids Surf B Biointerfaces 2015; 128: 405-9.
[http://dx.doi.org/10.1016/j.colsurfb.2015.02.038] [PMID: 25766924]
[87]
Doppalapudi S, Jain A, Chopra DK, Khan W. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur J Pharm Sci 2017; 96: 515-29.
[http://dx.doi.org/10.1016/j.ejps.2016.10.025] [PMID: 27777066]
[88]
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54(Suppl. 1): S131-55.
[http://dx.doi.org/10.1016/S0169-409X(02)00118-7] [PMID: 12460720]
[89]
Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 1993; 89(1): R9-R12.
[http://dx.doi.org/10.1016/0378-5173(93)90313-5]
[90]
Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 2003; 56(2): 189-96.
[http://dx.doi.org/10.1016/S0939-6411(03)00067-5] [PMID: 12957632]
[91]
Arora R, Katiyar SS, Kushwah V, Jain S. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: A comparative study. Expert Opin Drug Deliv 2017; 14(2): 165-77.
[http://dx.doi.org/10.1080/17425247.2017.1264386] [PMID: 27882780]
[92]
Pradhan M, Singh D, Singh MR. Development characterization and skin permeating potential of lipid based novel delivery system for topical treatment of psoriasis. Chem Phys Lipids 2015; 186: 9-16.
[http://dx.doi.org/10.1016/j.chemphyslip.2014.11.004] [PMID: 25447290]
[93]
Boakye CHA, Patel K, Doddapaneni R, Bagde A, Marepally S, Singh M. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. J Control Release 2017; 246: 120-32.
[http://dx.doi.org/10.1016/j.jconrel.2016.05.017] [PMID: 27170227]
[94]
Kang NW, Kim MH, Sohn SY, et al. Curcumin-loaded lipid-hybridized cellulose nanofiber film ameliorates imiquimod-induced psoriasis-like dermatitis in mice. Biomaterials 2018; 182: 245-58.
[http://dx.doi.org/10.1016/j.biomaterials.2018.08.030] [PMID: 30142524]
[95]
Lin CY, Hsu CY, Elzoghby AO, Alalaiwe A, Hwang TL, Fang JY. Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions. Acta Biomater 2019; 90: 350-61.
[http://dx.doi.org/10.1016/j.actbio.2019.04.002] [PMID: 30951898]
[96]
Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm 2010; 401(1-2): 93-102.
[http://dx.doi.org/10.1016/j.ijpharm.2010.09.007] [PMID: 20858539]
[97]
Pinto MF, Moura CC, Nunes C, Segundo MA, Costa LSA, Reis S. A new topical formulation for psoriasis: Development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm 2014; 477(1-2): 519-26.
[http://dx.doi.org/10.1016/j.ijpharm.2014.10.067] [PMID: 25445970]
[98]
Pradhan M, Singh D, Singh MR. Fabrication, optimization and characterization of triamcinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis: Application of box behnken design, in vitro and ex vivo studies. J Drug Deliv Sci Technol 2017; 41: 325-33.
[http://dx.doi.org/10.1016/j.jddst.2017.07.024]
[99]
Ainbinder D, Paolino D, Fresta M, Touitou E. Drug delivery applications with ethosomes. J Biomed Nanotechnol 2010; 6(5): 558-68.
[http://dx.doi.org/10.1166/jbn.2010.1152] [PMID: 21329048]
[100]
Kumar KP, Radhika PR, Sivakumar T. Ethosomes-a priority in transdermal drug delivery. Int J Adv Pharm Sci 2010; 1(2): 111-21.
[http://dx.doi.org/10.5138/ijaps.2010.0976.1055.01012]]
[101]
Zhang Y, Xia Q, Li Y, et al. CD44 assists the topical anti-psoriatic efficacy of curcumin-loaded hyaluronan-modified ethosomes: A new strategy for clustering drug in inflammatory skin. Theranostics 2019; 9(1): 48-64.
[http://dx.doi.org/10.7150/thno.29715] [PMID: 30662553]
[102]
Korade S, Deshmukh MT, Shete RV. Formulation and evaluation of ethosomal gel containing clobetasol. Indian J Pharm Sci 2016; 3: 664-72.
[103]
Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007; 123(2): 148-54.
[http://dx.doi.org/10.1016/j.jconrel.2007.08.005] [PMID: 17884226]
[104]
Abolmaali SS, Tamaddon AM, Farvadi FS, Daneshamuz S, Moghimi H. Pharmaceutical nanoemulsions and their potential topical and transdermal applications. Indian J Pharm Sci 2011; 7(3): 139-50.
[105]
Shafiq-un-Nabi S, Shakeel F, Talegaonkar S, et al. Formulation development and optimization using nanoemulsion technique: A technical note. AAPS PharmSciTech 2007; 8(2): 28.
[http://dx.doi.org/10.1208/pt0802028] [PMID: 17622106]
[106]
Rajitha P, Shammika P, Aiswarya S, Gopikrishnan A, Jayakumar R, Sabitha M. Chaulmoogra oil based methotrexate loaded topical nanoemulsion for the treatment of psoriasis. J Drug Deliv Sci Technol 2019; 49: 463-76.
[http://dx.doi.org/10.1016/j.jddst.2018.12.020]
[107]
Kaur A, Katiyar SS, Kushwah V, Jain S. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine (Lond) 2017; 13(4): 1473-82.
[http://dx.doi.org/10.1016/j.nano.2017.02.009] [PMID: 28259803]
[108]
Espinoza LC, Silva-Abreu M, Calpena AC, et al. Nanoemulsion strategy of pioglitazone for the treatment of skin inflammatory diseases. Nanomedicine (Lond) 2019; 19: 115-25.
[http://dx.doi.org/10.1016/j.nano.2019.03.017] [PMID: 31004811]
[109]
Bernardi DS, Pereira TA, Maciel NR, et al. Formation and stability of oil-in-water nanoemulsions containing rice bran oil: In vitro and in vivo assessments. J Nanobiotechnology 2011; 9(1): 44.
[http://dx.doi.org/10.1186/1477-3155-9-44] [PMID: 21952107]
[110]
Romero GB, Arntjen A, Keck CM, Müller RH. Amorphous cyclosporin A nanoparticles for enhanced dermal bioavailability. Int J Pharm 2016; 498(1-2): 217-24.
[http://dx.doi.org/10.1016/j.ijpharm.2015.12.019] [PMID: 26688038]
[111]
Desmet E, Bracke S, Forier K, et al. An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis. Int J Pharm 2016; 500(1-2): 268-74.
[http://dx.doi.org/10.1016/j.ijpharm.2016.01.042] [PMID: 26806466]
[112]
Barradas TN, Senna JP, Cardoso SA, et al. Hydrogel-thickened nanoemulsions based on essential oils for topical delivery of psoralen: Permeation and stability studies. Eur J Pharm Biopharm 2017; 116: 38-50.
[http://dx.doi.org/10.1016/j.ejpb.2016.11.018] [PMID: 27867112]
[113]
Barradas TN, Senna JP, Cardoso SA, de Holanda E, Silva KG. Elias Mansur CR. Formulation characterization and in vitro drug release of hydrogel-thickened nanoemulsions for topical delivery of 8-methoxypsoralen. Mater Sci Eng C 2018; 92: 245-53.
[http://dx.doi.org/10.1016/j.msec.2018.06.049] [PMID: 30184748]
[114]
Oliveira CA, Gouvêa MM, Antunes GR, Freitas ZMF, Marques FFC, Ricci-Junior E. Nanoemulsion containing 8-methoxypsoralen for topical treatment of dermatoses: Development, characterization and ex vivo permeation in porcine skin. Int J Pharm 2018; 547(1-2): 1-9.
[http://dx.doi.org/10.1016/j.ijpharm.2018.05.053] [PMID: 29800737]
[115]
Gheorghe I, Saviuc C, Ciubuca B, Lazar V, Chifiriuc MC. Nanodrug delivery systems for transdermal drug delivery. In: Grumezescu AM, Ed.Nanomaterials for Drug Delivery and Therapy. Newyork: William Andrew Publishers-Elsevier 2019; pp. 225-44.
[http://dx.doi.org/10.1016/B978-0-12-816505-8.00010-2]
[116]
Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim Biophys Acta 2001; 1514(2): 191-205.
[http://dx.doi.org/10.1016/S0005-2736(01)00369-8] [PMID: 11557020]
[117]
Gizaway SE, Fadel M, Mourad B, Elnaby FEZ. Betamethasone dipropionate gel for treatment of localised plaque psoriasis. Int J Pharm Pharm Sci 2017; 9(8): 173-82.
[http://dx.doi.org/10.22159/ijpps.2017v9i8.18571]
[118]
Mishra DK, Shandilya R, Mishra PK. Lipid based nanocarriers: A translational perspective. Nanomedicine (Lond) 2018; 14(7): 2023-50.
[http://dx.doi.org/10.1016/j.nano.2018.05.021] [PMID: 29944981]
[119]
Raza K, Katare OP, Setia A, Bhatia A, Singh B. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J Microencapsul 2013; 30(3): 225-36.
[http://dx.doi.org/10.3109/02652048.2012.717115] [PMID: 23088318]
[120]
Abdelgawad R, Nasr M, Moftah NH, Hamza MY. Phospholipid membrane tubulation using ceramide doping “Cerosomes”: Charac-terization and clinical application in psoriasis treatment. Eur J Pharm Sci 2017; 101: 258-68.
[http://dx.doi.org/10.1016/j.ejps.2017.02.030] [PMID: 28232140]
[121]
Batheja P, Sheihet L, Kohn J, Singer AJ, Michniak-Kohn B. Topical drug delivery by a polymeric nanosphere gel: Formulation op-timization and in vitro and in vivo skin distribution studies. J Control Release 2011; 149(2): 159-67.
[http://dx.doi.org/10.1016/j.jconrel.2010.10.005] [PMID: 20950659]
[122]
Kilfoyle BE, Sheihet L, Zhang Z, Laohoo M, Kohn J, Michniak-Kohn BB. Development of paclitaxel-TyroSpheres for topical skin treatment. J Control Release 2012; 163(1): 18-24.
[http://dx.doi.org/10.1016/j.jconrel.2012.06.021] [PMID: 22732474]
[123]
Beber TC, de Andrade DF, Chaves Pdos S, Pohlmann AR, Guterres SS, Beck RC. Cationic polymeric nanocapsules as a strategy to target dexamethasone to viable epidermis: Skin penetration and permeation studies. J Nanosci Nanotechnol 2016; 16(2): 1331-8.
[http://dx.doi.org/10.1166/jnn.2016.11670] [PMID: 27433583]
[124]
Marchiori ML, Lubini G, Dalla Nora G, et al. Hydrogel containing dexamethasone-loaded nanocapsules for cutaneous administration: Preparation, characterization, and in vitro drug release study. Drug Dev Ind Pharm 2010; 36(8): 962-71.
[http://dx.doi.org/10.3109/03639041003598960] [PMID: 20590450]
[125]
Mao KL, Fan ZL, Yuan JD, et al. Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model. Colloids Surf B Biointerfaces 2017; 160: 704-14.
[http://dx.doi.org/10.1016/j.colsurfb.2017.10.029] [PMID: 29035818]
[126]
Tripathi PK, Gorain B, Choudhury H, Srivastava A, Kesharwani P. Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon 2019; 5(3)e01343
[http://dx.doi.org/10.1016/j.heliyon.2019.e01343] [PMID: 30957038]
[127]
Agrawal U, Mehra NK, Gupta U, Jain NK. Hyperbranched dendritic nano-carriers for topical delivery of dithranol. J Drug Target 2013; 21(5): 497-506.
[http://dx.doi.org/10.3109/1061186X.2013.771778] [PMID: 23594093]
[128]
Gabriel D, Mugnier T, Courthion H, et al. Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis. J Control Release 2016; 242: 16-24.
[http://dx.doi.org/10.1016/j.jconrel.2016.09.007] [PMID: 27639683]
[129]
Ferreira M, Barreiros L, Segundo MA, et al. Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management. Colloids Surf B Biointerfaces 2017; 159: 23-9.
[http://dx.doi.org/10.1016/j.colsurfb.2017.07.080] [PMID: 28779637]
[130]
Gupta S, Bansal R, Gupta S, Jindal N, Jindal A. Nanocarriers and nanoparticles for skin care and dermatological treatments. Indian Dermatol Online J 2013; 4(4): 267-72.
[http://dx.doi.org/10.4103/2229-5178.120635] [PMID: 24350003]
[131]
Palmer BC, DeLouise LA. Nanoparticle-enabled transdermal drug delivery systems for enhanced dose control and tissue targeting. Molecules 2016; 21(12): 1719.
[http://dx.doi.org/10.3390/molecules21121719] [PMID: 27983701]
[132]
Bessar H, Venditti I, Benassi L, et al. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids Surf B Biointerfaces 2016; 141: 141-7.
[http://dx.doi.org/10.1016/j.colsurfb.2016.01.021] [PMID: 26852097]
[133]
Nemati H, Ghahramani MH, Faridi-Majidi R, et al. Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. J Control Release 2017; 268: 259-68.
[http://dx.doi.org/10.1016/j.jconrel.2017.10.034] [PMID: 29074408]
[134]
Crisan D, Scharffetter-Kochanek K, Crisan M, et al. Topical silver and gold nanoparticles complexed with Cornus mas suppress inflammation in human psoriasis plaques by inhibiting NF-κB activity. Exp Dermatol 2018; 27(10): 1166-9.
[http://dx.doi.org/10.1111/exd.13707] [PMID: 29906306]
[135]
Zhang J, Li X, Wei J, et al. Gallic acid inhibits the expression of keratin 16 and keratin 17 through Nrf2 in psoriasis-like skin disease. Int Immunopharmacol 2018; 65: 84-95.
[http://dx.doi.org/10.1016/j.intimp.2018.09.048] [PMID: 30293051]
[136]
Acosta EH, Pérez JAS, Arjona JA, Visioli F. An olive polyphenol-based nutraceutical improves cutaneous manifestations of psoriasis in humans. PharmaNutrition 2016; 4(4): 151-3.
[http://dx.doi.org/10.1016/j.phanu.2016.10.002]
[137]
Chen Q, Zhou H, Yang Y, et al. Investigating the potential of oxymatrine as a psoriasis therapy. Chem Biol Interact 2017; 271: 59-66.
[http://dx.doi.org/10.1016/j.cbi.2017.04.020] [PMID: 28450041]
[138]
Chiang HM, Lin YT, Hsiao PL, Su YH, Tsao HT, Wen KC. Determination of marked components–aloin and aloe-emodin-in Aloe vera before and after hydrolysis. Yao Wu Shi Pin Fen Xi 2012; 20: 646-52.
[http://dx.doi.org/10.6227/jfda.2012200311]
[139]
Reddy S, Aggarwal BB. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett 1994; 341(1): 19-22.
[http://dx.doi.org/10.1016/0014-5793(94)80232-7] [PMID: 7511111]
[140]
Nardo VD, Gianfaldoni S, Tchernev G, et al. Use of curcumin in psoriasis. Open Access Maced J Med Sci 2018; 6(1): 218-20.
[http://dx.doi.org/10.3889/oamjms.2018.055] [PMID: 29484027]
[141]
Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005; 11(1): 43-9.
[http://dx.doi.org/10.1038/nm1162] [PMID: 15592573]
[142]
Pazyar N, Yaghoobi R. Soybean: A potential antipsoriasis agent. Jundishapur J Nat Pharm Prod 2015; 10(1)e20924
[http://dx.doi.org/10.17795/jjnpp-20924] [PMID: 25866722]
[143]
Kumar VS, Navaratnam V. Neem (Azadirachta indica): Prehistory to contemporary medicinal uses to humankind. Asian Pac J Trop Biomed 2013; 3(7): 505-14.
[http://dx.doi.org/10.1016/S2221-1691(13)60105-7] [PMID: 23835719]
[144]
Janeczek M, Moy L, Lake EP, Swan J. Review of the efficacy and safety of topical mahonia aquifolium for the treatment of psoriasis and atopic dermatitis. J Clin Aesthet Dermatol 2018; 11(12): 42-7.
[PMID: 30666279]
[145]
Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986; 15(3): 504-7.
[http://dx.doi.org/10.1016/S0190-9622(86)70201-6] [PMID: 3760276]
[146]
Raut G, Wairkar S. Management of psoriasis with nutraceuticals: An update. Complement Ther Clin Pract 2018; 31: 25-30.
[http://dx.doi.org/10.1016/j.ctcp.2018.01.007] [PMID: 29705464]
[147]
Escobar SO, Achenbach R, Iannantuono R, Torem V. Topical fish oil in psoriasis--a controlled and blind study. Clin Exp Dermatol 1992; 17(3): 159-62.
[http://dx.doi.org/10.1111/j.1365-2230.1992.tb00194.x] [PMID: 1451289]
[148]
Fan T, Wang S, Yu L, et al. Treating psoriasis by targeting its susceptibility gene Rel. Clin Immunol 2016; 165: 47-54.
[http://dx.doi.org/10.1016/j.clim.2016.03.009] [PMID: 26993753]
[149]
Ford PC, Ford RJ, Swanson S. A study of psoriasis: A methodological critique MS Thesis Portland State University 1979.
[http://dx.doi.org/10.15760/etd.2684]
[150]
Gray SG, Lawlis GF. A case study of pruritic eczema treated by relaxation and imagery. Psychol Rep 1982; 51(2): 627-33.
[http://dx.doi.org/10.2466/pr0.1982.51.2.627] [PMID: 6758013]
[151]
Waxman D. Behaviour therapy of psoriasis--a hypnoanalytic and counter-conditioning technique. Postgrad Med J 1973; 49(574): 591-5.
[http://dx.doi.org/10.1136/pgmj.49.574.591] [PMID: 4788839]
[152]
Frankel FH, Misch RC. Hypnosis in a case of long-standing psoriasis in a person with character problems. Int J Clin Exp Hypn 1973; 21(3): 121-30.
[http://dx.doi.org/10.1080/00207147308409117] [PMID: 4701785]
[153]
Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients Acta dermato-venereologic 2014; 94(3) (293): 297.
[http://dx.doi.org/10.2340/00015555-1719]
[154]
Shenefelt PD. Biofeedback, cognitive-behavioral methods, and hypnosis in dermatology: Is it all in your mind? Dermatol Ther 2003; 16(2): 114-22.
[http://dx.doi.org/10.1046/j.1529-8019.2003.01620.x] [PMID: 12919113]
[155]
Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis. J Invest Dermatol 2014; 134(6): 1542-51.
[http://dx.doi.org/10.1038/jid.2013.508] [PMID: 24284419]
[156]
Kimball AB, Wu EQ, Guérin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol 2012; 67(4): 651-7.
[http://dx.doi.org/10.1016/j.jaad.2011.11.948] [PMID: 22243764]
[157]
Tohid H, Aleem D, Jackson C. Major depression and psoriasis: A psychodermatological phenomenon. Skin Pharmacol Physiol 2016; 29(4): 220-30.
[http://dx.doi.org/10.1159/000448122] [PMID: 27536769]
[158]
Thorslund K, Svensson T, Nordlind K, Ekbom A, Fored CM. Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: A population-based cohort study. J Intern Med 2013; 274(3): 281-7.
[http://dx.doi.org/10.1111/joim.12093] [PMID: 23711088]
[159]
Alpsoy E, Özcan E, Çetin L, et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent mo-clobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol 1998; 38(2 Pt 1): 197-200.
[http://dx.doi.org/10.1016/S0190-9622(98)70240-3] [PMID: 9486674]
[160]
Modell JG, Boyce S, Taylor E, Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: A pilot study. Psychosom Med 2002; 64(5): 835-40.
[PMID: 12271115]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2020
Published on: 27 January, 2020
Page: [82 - 104]
Pages: 23
DOI: 10.2174/1574886315666200128095958
Price: $65

Article Metrics

PDF: 69
HTML: 5